Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER IMMUNOTHERAPY

Tumor-infiltrating lymphocytes make inroads in non–small-cell lung cancer

A phase 1 trial shows promising anti-tumor activity of tumor-infiltrating-lymphocyte therapy in patients with advanced non–small-cell lung cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Procedure for the generation of TILs for adoptive cell-transfer therapy.

References

  1. 1.

    Sharma, P. & Allison, J. P. Nat. Rev. Immunol. 20, 75–76 (2020).

    CAS  Article  Google Scholar 

  2. 2.

    Dudley, M. E. et al. J. Clin. Oncol. 26, 5233–5239 (2008).

    CAS  Article  Google Scholar 

  3. 3.

    Stevanovic, S. et al. Clin. Cancer Res. 25, 1486–1493 (2019).

    CAS  Article  Google Scholar 

  4. 4.

    Tran, E. et al. Science 344, 641–645 (2014).

    CAS  Article  Google Scholar 

  5. 5.

    Tran, E. et al. N. Engl. J. Med. 375, 2255–2262 (2016).

    CAS  Article  Google Scholar 

  6. 6.

    Zacharakis, N. et al. Nat. Med. 24, 724–730 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    Creelan, B. C. et al. Nat. Med. https://doi.org/10.1038/s41591-021-01462-y (2021).

    Article  Google Scholar 

  8. 8.

    Ghorani, E. et al. Nat. Can. 1, 546–561 (2020).

    Article  Google Scholar 

  9. 9.

    Muranski, P. et al. Nat. Clin. Pract. Oncol. 3, 668–681 (2006).

    CAS  Article  Google Scholar 

  10. 10.

    Siddiqui, I. et al. Immunity 50, 195–211.e110 (2019).

    CAS  Article  Google Scholar 

  11. 11.

    Krishna, S. et al. Science 370, 1328–1334 (2020).

    CAS  Article  Google Scholar 

  12. 12.

    Alspach, E. et al. Nature 574, 696–701 (2019).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Stanley R. Riddell.

Ethics declarations

Competing interests

S.R.R. holds equity in and consults for Lyell Immunopharma and Adaptive Biotechnologies. S.R.R. is an inventor of patents licensed to Bristol Myers Squibb, and S.R.R. and J.R.V. are inventors on intellectual property that is licensed to Lyell Immunopharma.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Veatch, J.R., Simon, S. & Riddell, S.R. Tumor-infiltrating lymphocytes make inroads in non–small-cell lung cancer. Nat Med 27, 1339–1341 (2021). https://doi.org/10.1038/s41591-021-01445-z

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing